Anti-VEGF protein compositions and methods for producing the same

Patent metadata

Field	Value
Publication number	US-11732025-B2
Application number	US-202217994223-A
Country	US
Kind code	B2
Filing date	Nov 25, 2022
Priority date	Dec 6, 2019
Publication date	Aug 22, 2023
Grant date	Aug 22, 2023

Abstract

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

First claim

What is claimed is:

1. A method of producing aflibercept from a host cell cultured in a chemically defined medium (CDM), comprising:
(a) culturing said host cell in said CDM under suitable conditions in which said host cell expresses aflibercept wherein (i) the cumulative concentration of nickel in said CDM is less than or equal to 0.4 (ii) the cumulative concentration of iron in said CDM is less than or equal to 55.0 (iii) the cumulative concentration of copper in said CDM is less than or equal to 0.8 (iv) the cumulative concentration of zinc in said CDM is less than or equal to 56.0 (v) the cumulative concentration of cysteine in said CDM is less than or equal to 10.0 mM, or (vi) the cumulative concentration of an antioxidant in said CDM is 0.001 mM to 10.0 mM for any single anti-oxidant and the cumulative concentration of all anti-oxidants is less than or equal to 30.0 mM;
(b) binding aflibercept from said clarified harvest to a Protein A resin;
(c) eluting said aflibercept of step (b) forming an affinity eluate, and subjecting said eluate comprising aflibercept to anion exchange chromatography (AEX); and
(d) collecting a flowthrough fraction, wherein said aflibercept of step d) has a glycosylation profile based on molar percentage selected from the group consisting of 40% to 50% total fucosylated glycans, 30% to 55% total sialylated glycans, 2% to 15% mannose-5, and 60% to 79% galactosylated glycans.

2. The method of claim 1 , wherein said aflibercept of step d) has 40% to 50% total fucosylated glycans.

3. The method of claim 1 , wherein said aflibercept of step d) has 30% to 55% total sialylated glycans.

4. The method of claim 1 , wherein said aflibercept of step d) has 2% to 15% mannose-5.

5. The method of claim 1 , wherein said aflibercept of step d) has 60% to 79% galactosylated glycans.

6. The method of claim 1 , wherein said aflibercept of step d) is glycosylated at one or more Asparagines as follows: G0-GlcNAc glycosylation; G1-GlcNAc glycosylation; G1S-GlcNAc glycosylation; G0 glycosylation; G1 glycosylation; G1S glycosylation; G2 glycosylation; G2S glycosylation; G2S2 glycosylation; G0F glycosylation; G2F2S glycosylation; G2F2S2 glycosylation; G1F glycosylation; G1FS glycosylation; G2F glycosylation; G2FS glycosylation; G2FS2 glycosylation; G3FS glycosylation; G3FS3 glycosylation; G0-2GlcNAc glycosylation; Man4 glycosylation; Man4_A1G1 glycosylation; Man4_A1G1S1 glycosylation; Man5 glycosylation; Man5_A1G1 glycosylation; Man5_A1G1S1 glycosylation; Man6 glycosylation; Man6_G0+Phosphate glycosylation; Man6+Phosphate glycosylation; and/or Man7 glycosylation.

7. The method of claim 1 , wherein said affinity eluate has a first color and said flowthrough fraction has a second color and wherein said second color is less intense yellow-brown in color when said affinity eluate and said flowthrough fraction protein concentrations are normalized.

8. The method of claim 1 , wherein said cell is selected from the group consisting of CHO, NS0, Sp2/0, embryonic kidney cells and BHK.

9. The method of claim 1 , further comprising aflibercept that includes oxidized species of aflibercept that have at least one oxidized amino acid residue selected from the group consisting of tryptophan, histidine, phenylalanine, tyrosine and a combination thereof.

10. The method of claim 9 , wherein said oxidized amino acid residue of aflibercept is Trp58 and Trp138 and the relative amounts in step (a) is reduced by at least 10% after step (d).

11. The method of claim 9 , wherein the relative amounts of oxidized Trp58 and Trp138 in aflibercept after step (b) is at least 0.4% and 2.0% of the total amount of aflibercept.

12. The method of claim 9 , wherein said oxidized amino acid residue of aflibercept is His19, His86, and His95 and the relative amounts in step (a) is reduced by at least 10% after step (d).

13. The method of claim 9 , wherein the relative amounts of oxidized His19, His86, and His95 in aflibercept after step (b) is at least 0.05% of the total amount of aflibercept.

14. The method of claim 9 , wherein the relative amounts of oxidized His19, His86, and His95 in aflibercept after step (b) is at least 0.1% the total amount of aflibercept.

15. The method of claim 9 , wherein the relative amounts of oxidized His19, His86, and His95 in aflibercept after step (d) comprises less than 0.05% of the total amount of aflibercept.

16. The oxo-aflibercept composition of claim 1 , wherein the N-glycosylation of the F(ab′)2 portion of said oxo-aflibercept at Asn36 is between 98.3% and 99.4%.

17. The oxo-aflibercept composition of claim 1 , wherein the N-glycosylation of the F(ab′)2 portion of said oxo-aflibercept at Asn68 is between 51.9% and 64.9%.

18. The oxo-aflibercept composition of claim 1 , wherein the N-glycosylation of the F(ab′)2 portion of said oxo-aflibercept at Asn123 is between 98.4% and 99.9%.

19. The oxo-aflibercept composition of claim 1 , wherein the N-glycosylation of the F(ab′)2 portion of said oxo-aflibercept at Asn196 is between 55.1% and 98.6%.

20. A method of producing aflibercept from a host cell cultured in a chemically defined medium (CDM), comprising:
(a) culturing said host cell in said CDM under suitable conditions in which said host cell expresses aflibercept wherein the cumulative concentration of the following metals in said CDM at the time of harvest can be measured and falls within the following ranges:
(i) nickel is less than or equal to 0.4 μM,
(ii) iron is than or equal to 55.0 μM,
(iii) copper is less than or equal to 0.8 μM, and
(iv) zinc is less than or equal to 56.0 μM,

(b) binding aflibercept from said clarified harvest to a Protein A resin;
(c) eluting said aflibercept of step (b) forming an affinity eluate, and subjecting said eluate comprising aflibercept to anion exchange chromatography (AEX); and
(d) collecting a flowthrough fraction, wherein said aflibercept of step d) has a glycosylation profile based on molar percentage selected from the group consisting of 40% to 50% total fucosylated glycans, 30% to 55% total sialylated glycans, 2% to 15% mannose-5, and 60% to 79% galactosylated glycans.

21. The method of claim 20 , wherein said aflibercept of step d) has 40% to 50% total fucosylated glycans.

22. The method of claim 20 , wherein said aflibercept of step d) has 30% to 55% total sialylated glycans.

23. The method of claim 20 , wherein said aflibercept of step d) has 2% to 15% mannose-5.

24. The method of claim 20 , wherein said aflibercept of step d) has 60% to 79% galactosylated glycans.

25. The method of claim 20 , wherein said aflibercept of step d) is glycosylated at one or more Asparagines as follows: G0-GlcNAc glycosylation; G1-GlcNAc glycosylation; G1S-GlcNAc glycosylation; G0 glycosylation; G1 glycosylation; G1S glycosylation; G2 glycosylation; G2S glycosylation; G2S2 glycosylation; G0F glycosylation; G2F2S glycosylation; G2F2S2 glycosylation; G1F glycosylation; G1FS glycosylation; G2F glycosylation; G2FS glycosylation; G2FS2 glycosylation; G3FS glycosylation; G3FS3 glycosylation; G0-2GlcNAc glycosylation; Man4 glycosylation; Man4_A1G1 glycosylation; Man4_A1G1S1 glycosylation; Man5 glycosylation; Man5_A1G1 glycosylation; Man5_A1G1S1 glycosylation; Man6 glycosylation; Man6_G0+Phosphate glycosylation; Man6+Phosphate glycosylation; and/or Man7 glycosylation.

26. The method of claim 20 , wherein said affinity eluate has a first color and said flowthrough fraction h

Assignees

• Regeneran Pharmaceuticals Inc
• Regeneron Pharma

Inventors

• Wang Shunhai
• Li Ning
• Chen Hunter
• Bhupender Bhalla Amardeep Singh
• Lawrence Shawn
• Johnson Amy
• Casey Meghan
• Grapel Jaimie

Classifications

• C12N2529/10

  Stimulation by light · CPC title

• C12N15/85

  for animal cells · CPC title

• C07K1/06

  using protecting groups or activating agents {(C07K1/003, C07K1/006 take precedence)} · CPC title

• C12N2510/02

  Cells for production · CPC title

• C07K1/165

  mixed-mode chromatography · CPC title